Home Contact Center Add this

Decapeptyl®, Neo Decapeptyl®, Trelstar®, Pamorelin®

Triptorelin is a gonadotropin releasing hormone (GnRH) agonist

Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females).

Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the quality of life of patients. GnRH agonist treatment achieves similar overall survival rates in advanced prostate cancer as surgical castration.The triptorelin 1-month, 3-month and 6-month sustained release formulations have provided patients with a convenient treatment modality.

Decapeptyl®, Neo Decapeptyl®, Trelstar®, Pamorelin®

In short

inshort-image1

GnRH discovered by Professor Andrew Schally (1971 - Tulane University), who received the Nobel Prize in 1977 for his discovery. The first synthesis of GnRH agonist Triptorelin by Professor Andrew Schally was in 1973.

inshort-image2

Triptorelin is number one product of Ipsen in 2014.

Overview of the products

Indications

Advanced prostate cancer
Endometriosis
In-vitro fertilization programs
Uterine fibroids
Precocious puberty

Product Characteristics

3 dosages:
1-month (3.75 mg)
3-month (11.2 mg)
6-month (22.5 mg)

Debiopharm Value Added

  • Development and registration of the triptorelin 1-, 3- and 6-month sustained release formulations in Europe, in North America and the rest of the world
  • Continuous life cycle management (new formulations, route of administration, indications)

 

  • First worldwide registered sustained release formulation of a gonadotropin releasing hormone (GnRH) agonist in 1986.

Commercial Map

  • Aché
    • Brazil
  • Allergan
    • Canada
    • USA
  • Dr. Reddy’s Laboratories
    • India
  • Ferring Pharmaceuticals
    • Israel
  • Ipsen
    • Algeria
    • Andorra
    • Armenia
    • Australia
    • Austria
    • Azerbaijan
    • Balearic islands
    • Belarus
    • Belgium
    • Burkina faso
    • China
    • Cyprus
    • Costa rica
    • Czech republic
    • Danemark
    • Estonia
    • España
    • Finland
    • France & Monaco
    • French Guiana
    • French Polynesia
    • Georgia
    • Germany
    • Greece
    • Guadeloupe
    • Hong-kong
    • Hungary
    • Irak
    • Iran
    • Irland
    • Italy, San Marino, Vatican City
    • Jordan
    • Kazakhstan
    • Kuweit
    • Latvia
    • Lebanon
    • Lithuania
    • Luxembourg
    • Madagascar
    • Martinique
    • Mauritius
    • Mayotte, Grande terre and Paman
    • Moldova
    • Morocco
    • Netherlands
    • New caledonia
    • Panama and Panama canal zone
    • Poland
    • Portugal Azores and Madeira
    • Réunion
    • Romania
    • Russian federation
    • Serbia
    • Montenegro
    • Slovakia
    • Slovenia
    • South korea
    • Sweden
    • Tunisia
    • Ukraine
    • United Arab Emirates
    • United kindgom
    • Uzbekistan
    • Vietnam
    • Wallis and Futuna islands
  • Orient EuroPharma
    • Singapore
  • Tecnofarma
    • Argentina
    • Bolivia
    • Chile
    • Colombia
    • Dominican Republic
    • Ecuador
    • Mexico
    • Paraguay
    • Peru
    • Uruguay
    • Venezuela
  • United Laboratories Inc
    • Philippines
  • Vifor Pharma
    • Switzerland

Related Press release